Diabetes Care, Vol 18, Issue 2 188-192, Copyright © 1995 by American Diabetes Association

ARTICLES

Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy

NL Eibl, HP Kopp, HR Nowak, CJ Schnack, PG Hopmeier and G Schernthaner
First Department of Medicine, Rudolfstiftung Hospital, Vienna, Austria.

OBJECTIVE--To investigate the effects of long-term high-dose oral magnesium (Mg) therapy (30 mmol/day) in patients with type II diabetes. Low plasma magnesium levels have been reported in type II diabetes and are associated with insulin resistance and diabetic late complications. RESEARCH DESIGN AND METHODS--Forty patients with type II diabetes and hypomagnesemia were observed in a randomized double-blind placebo-controlled trial for 3 months (body mass index: 28 +/- 4 kg/m2; HbA1c: 7.4 +/- 0.8%). Plasma and urine magnesium and metabolic control parameters were determined, and side effects were considered, especially with regard to patients' compliance. RESULTS--A significant increase in plasma magnesium levels was observed after 3 months of treatment (Mg: 0.73 +/- 0.8 vs. 0.81 +/- 0.1 mmol/l), reaching magnesium levels of the control group (0.88 +/- 0.8 mmol/l; NS); metabolic control, however, was not altered (HbA1c: 7.2 +/- 0.7 vs. 7.4 +/- 0.9%). Six months after the end of the trial, plasma magnesium declined to pretreatment levels (Mg: 0.73 +/- 0.07 mmol/l). The prevalence of side effects was high at the beginning and was reduced significantly during treatment. CONCLUSIONS--We conclude that oral magnesium replacement therapy corrects hypomagnesemia after a minimum treatment period of 3 months. These observations might be important for the prevention of diabetic late complications.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P.-C. T. Pham, P.-M. T. Pham, S. V. Pham, J. M. Miller, and P.-T. T. Pham Hypomagnesemia in Patients with Type 2 Diabetes Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 366 - 373. [Abstract] [Full Text] [PDF]

				S. Bo, M. Durazzo, S. Guidi, M. Carello, C. Sacerdote, B. Silli, R. Rosato, M. Cassader, L. Gentile, and G. Pagano Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 1062 - 1069. [Abstract] [Full Text] [PDF]

				Y. Song, J. E. Manson, J. E. Buring, and S. Liu Dietary Magnesium Intake in Relation to Plasma Insulin Levels and Risk of Type 2 Diabetes in Women Diabetes Care, January 1, 2004; 27(1): 59 - 65. [Abstract] [Full Text] [PDF]

				R. Lopez-Ridaura, W. C. Willett, E. B. Rimm, S. Liu, M. J. Stampfer, J. E. Manson, and F. B. Hu Magnesium Intake and Risk of Type 2 Diabetes in Men and Women Diabetes Care, January 1, 2004; 27(1): 134 - 140. [Abstract] [Full Text] [PDF]

				M. Rodriguez-Moran and F. Guerrero-Romero Oral Magnesium Supplementation Improves Insulin Sensitivity and Metabolic Control in Type 2 Diabetic Subjects: A randomized double-blind controlled trial Diabetes Care, April 1, 2003; 26(4): 1147 - 1152. [Abstract] [Full Text] [PDF]

				G. Y. Yeh, D. M. Eisenberg, T. J. Kaptchuk, and R. S. Phillips Systematic Review of Herbs and Dietary Supplements for Glycemic Control in Diabetes Diabetes Care, April 1, 2003; 26(4): 1277 - 1294. [Abstract] [Full Text] [PDF]

				B. S. O'Connell Select Vitamins and Minerals in the Management of Diabetes Diabetes Spectr, August 1, 2001; 14(3): 133 - 148. [Abstract] [Full Text] [PDF]

				T. J. Orchard Magnesium and Type 2 Diabetes Mellitus Arch Intern Med, October 11, 1999; 159(18): 2119 - 2120. [Full Text] [PDF]